NGC Update Service: September 14, 2015
Agency for Healthcare Research and Quality (AHRQ) sent this bulletin at 09/14/2015 02:20 PM EDTSeptember 14, 2015
New This Week
Guideline SummariesAmerican Academy of Neurology Clinical Pharmacogenetics Implementation Consortium European Respiratory Society U.S. Preventive Services Task Force
|
Announcements
Conference News
- The Guidelines International Network (G-I-N) 12th annual conference will take place from October 7–10, 2015 in Amsterdam. The theme is "Engaging all stakeholders. Guidelines from a societal perspective." To register and book a pre-conference course, visit the G-I-N Conference Web site.
- Registration is now open for the Agency for Healthcare Research and Quality (AHRQ) 2015 Research Conference. It will be held October 4–6 at the Crystal Gateway Marriott Hotel and Convention Center in Crystal City, VA. The conference is titled "Producing Evidence and Engaging Partners to Improve Health Care." Visit the conference home page for more information.
- The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.
U.S. Food and Drug Administration (FDA) Advisories
- August 28, 2015: DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain: FDA is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors.
- September 10, 2015: Invokana and Invokamet (canagliflozin): Drug Safety Communication - New Information on Bone Fracture Risk and Decreased Bone Mineral Density: FDA has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density. To address these safety concerns, FDA added a new WARNING AND PRECAUTION and revised the ADVERSE REACTIONS section of the Invokana and Invokamet drug labels.
Health Awareness Topics - September 2015
- National Atrial Fibrillation Awareness Month (see related guidelines)
- National Sickle Cell Month (see related guidelines)
- National Traumatic Brain Injury Awareness Month (see related guidelines)
- Newborn Screening Awareness Month (see related guidelines)
- Ovarian Cancer Awareness Month (see related guidelines)
- Prostate Cancer Awareness Month (see related guidelines and guideline synthesis)
- Sepsis Awareness Month (see related guidelines)
- World Alzheimer's Month (see related guidelines)
How to Participate
- Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
- Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.
- Suggest a Guideline Synthesis Topic: We welcome your suggestions for guideline synthesis topics!
NGC's Sister Resource
Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).